toripalimab,nivolumab,tegafur,oxaliplatin,oteracil,gimeracil,capecitabine
nordic group,bms,coherus,otsuka,ono pharma,junshi biosciences
['toripalimab', ' tori ', 'attraction-5']
 masterfully breaking down the attraction-5 and toripalimab studies. wish we had pfs/os data for tori study, pathologic response always a risky primary endpoint. #asco23
Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded